Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It
Recent US registry data show that while most patients resemble those in key trials, just one in six get all four pillars of GDMT.
Recent US registry data show that while most patients resemble those in key trials, just one in six get all four pillars of GDMT.
In this feature interview, EP Lab Digest talks with Chirag Barbhaiya, MD, about his initial experience and first-in-human cases using the new MATRIX12 M esophageal…
New online learning is now freely available about critical appraisal of rapid reviews as part of Cochrane’s flagship Evidence Essentials modules for the public.
This Viewpoint discusses diagnosis of type 2 myocardial infarction.
With the approval of mavacamten, patients with hypertrophic cardiomyopathy now have more options, Steve Ommen says.
(8 April, 2024) Anastasia Shchendrygina, Clara Saldarriaga (18 January, 2024) Pascal Meier (17 January, 2024) Pascal Meier (13 March, 2024) Christian Smedberg, Rebecka Hultgren, Christian…
Your gift now to the American Heart Association will help save lives by funding pioneering medical research, education and prevention information and more. For 100…
70 y/o woman with a history of ischemic cardiomyopathy with ejection fraction of 20% due to a large healed anteroapical infarction. She had previously undergone…
Objectives Long-term follow-up of patients treated with trastuzumab largely focuses on those with reduced left ventricular ejection fraction (LVEF) on treatment completion. This study sought…
AbstractBackgroundIncrementing numbers of patients treated for attention-deficit/hyperactivity disorder (ADHD) call for scrutiny concerning long-term drug-safety.ObjectivesThis study aims to invest…